ArticlePloS one2025
Epidemiology of patients treated for multiple myeloma using a new algorithm in the French national health insurance database (SNDS): Results from the MYLORD study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparison of patient, hospitalization and center characteristics from the EMMY centers, IFM centers, and all multiple myeloma centers in France.Clinical hematology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundManagement of multiple myeloma (MM) has evolved in the last decade, impacting epidemiology and creating the need for a revised algorithm for patient identification in the French National Health Insurance database (SNDS). The objective of the MYLORD study was to provide up-to-date epidemiological indicators for MM using the SNDS.
methodsAdults treated for MM between 2014 and 2020 were identified using hospital stays (ICD-10 code C90*) and/or Long-Term Disease status for MM (ICD-10 C90*) and treatment dispensation (MM specific treatments), or lenalidomide or thalidomide with 2 conditions: at least 2 Serum or Urine-Protein Electrophoresis performed within 4 months after the first drug dispensing and no hospital stays for other indications than MM.
resultsIn 2020 in France, the number of new patients treated for MM was estimated at 5,608, corresponding to a world age-standardized incidence rate (ASIR) of 3.67 (3.55-3.78) per 100,000 patients. The total number of patients treated for MM was estimated at 33,675 corresponding to a world age-standardized prevalence rate (ASPR) of 22.34 (22.06-22.63) per 100,000 patients. The world ASIR slightly increased from 2014 to 2018, then slightly decreased until 2020. There is a regular increase of the ASPR every year in both men and women.
conclusionsThe algorithm developed for the MYLORD study considerably improves the identification of patients treated for MM in the SNDS compared to the current French references and allows to generate robust epidemiological indicators. The stable incidence and the increase in prevalence from 2014 to 2020 reflect the improvement in therapeutic management over the years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.